How could the CMS final rule for ESRD PPS affect Ascension?
Ascension may benefit from new ESRD reimbursement rates for DefenCath The final rule released by CMS establishes a new post-TDAPA Add-on payment of $8.32 per dialysis session for DefenCath during the first quarter of 2027. This rate is significantly higher than the current $2.37 rate in effect for the third and fourth quarters of 2026. CorMedix Therapeutics, the drug manufacturer, anticipates that the average Add-on rate for all four quarters in 2027 will exceed two times the current rate. As a major healthcare provider, Ascension could see increased revenue potential if its patients utilize DefenCath for ESRD treatment under the new payment structure.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Ascension
-
CMS finalized the 2027 End-Stage Renal Disease Prospective Payment System (ESRD PPS) final rule on October 28, 2026. The rule established a post-TDAPA Add-on payment of $8.32 per dialysis session for DefenCath® (taurolidine and heparin) for the first quarter of 2027, alongside a new quarterly process for calculating Add-On adjustments. This payment is three to five times higher than the $2.37 rate in effect during the third and fourth quarters of 2026.
The full event1independent outlet -
Ascension, as a large healthcare organization providing ESRD treatment, would benefit from the increased reimbursement rate for DefenCath. The drug manufacturer anticipates the average Add-on rate for 2027 will exceed two times the current rate of $2.37.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
faith-based healthcare organization and subsidiary of Ascension
Everything about Ascension
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- CMS released the 2027 ESRD PPS final rule on October 28, 2026.manilatimes.net
- The rule provides a post-TDAPA Add-on for DefenCath of $8.32 per dialysis session for Q1 of 2027.manilatimes.net
- The current rate for the third and fourth quarters of 2026 is $2.37.manilatimes.net
- CorMedix anticipates the average Add-on rate for all four quarters in 2027 will equate to more than 2x the current rate of $2.37.manilatimes.net
Why it matters
The reimbursement rate for specialized drugs like DefenCath is critical to the financial stability of dialysis providers. Changes in these rates directly influence the revenue generated from ESRD patients, which is a significant and ongoing area of healthcare expenditure.
Ascension operates within a highly regulated healthcare environment where CMS dictates payment structures. The shift to higher reimbursement rates for specific treatments could improve the financial viability of the organization's ESRD services, provided patient utilization of DefenCath remains consistent or increases.
What we don't know yet
- How will CMS apply certain utilization data in the Add-on calculations?
- Will Ascension's patient utilization of DefenCath increase or decrease under the new payment structure?
What would change this answer
Reporting
- manilatimes.netMonday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.